Last updated on February 2019

Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy


Brief description of study

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.

Clinical Study Identifier: NCT03404791

Find a site near you

Start Over

Chesapeake Urology

Hanover, MD United States
  Connect »

North Georgia Urology

Dalton, GA United States
  Connect »

North Austin Urology

Austin, TX United States
  Connect »

Urology of Virginia

Virginia Beach, VA United States
  Connect »

Mayo Clinic

Phoenix, AZ United States
  Connect »